Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers
- 26 October 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 75 (17), 1520-1526
- https://doi.org/10.1212/wnl.0b013e3181f9626a
Abstract
Background: Calcitonin gene–related peptide (CGRP) plays a fundamental role in the pathophysiology of neurovascular headaches. CGRP infusion causes headache and dilation of cranial vessels. However, it is unknown to what extent CGRP-induced vasodilation contributes to immediate head pain and whether the migraine-specific abortive drug sumatriptan, a 5-hydroxytryptamine 1B/1D agonist, inhibits CGRP-induced immediate vasodilation and headache. Methods: We performed a double-blind, randomized, placebo-controlled, crossover study in 18 healthy volunteers. We recorded circumference changes of the middle meningeal artery (MMA) and middle cerebral artery (MCA) using magnetic resonance angiography before and after infusion (20 minutes) of 1.5 μg/min human αCGRP or placebo (isotonic saline) as well as after a 6-mg sumatriptan subcutaneous injection. Results: Compared with placebo, CGRP caused significant dilation of MMA (p = 0.006) and no dilation of MCA (p = 0.69). Sumatriptan caused a marked contraction of MMA (15%–25.2%) and marginal contraction of MCA (3.9% to 5.3%). Explorative analysis revealed that sumatriptan had a more selective action on MMA compared with MCA on the CGRP day (p < 0.0001) and on the placebo day (p = 0.007). Conclusion: These data suggest that exogenous CGRP dilates extracranial vessels and not intracranial, and that sumatriptan exerts part of its antinociceptive action by constricting MMA and not MCA. Classification of evidence: This study provides Class I evidence that IV GCRP causes dilation of the MMA but not the MCA in healthy volunteers, and that sumatriptan reverses the dilation of the MMA caused by CGRP.This publication has 31 references indexed in Scilit:
- Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patientsThe Journal of Headache and Pain, 2008
- BIBN4096BS Antagonizes Human α-calcitonin Gene Related Peptide–induced Headache and Extracerebral Artery Dilatation*Clinical Pharmacology & Therapeutics, 2005
- The CGRP-Antagonist, BIBN4096BS Does not Affect Cerebral or Systemic Haemodynamics in Healthy VolunteersCephalalgia, 2005
- Calcitonin gene-related peptide and its role in migraine pathophysiologyEuropean Journal of Pharmacology, 2004
- Immunohistochemical Localization of Calcitonin Receptor–Like Receptor and Receptor Activity–Modifying Proteins in the Human Cerebral VasculatureJournal of Cerebral Blood Flow & Metabolism, 2002
- Cgrp May Play A Causative Role in MigraineCephalalgia, 2002
- Calcitonin gene-related peptide: Vasoactive effects and potential therapeutic roleGeneral Pharmacology: The Vascular System, 1996
- Vasoactive peptide release in the extracerebral circulation of humans during migraine headacheAnnals of Neurology, 1990
- Calcitonin gene-related peptide: functional role in cerebrovascular regulation.Proceedings of the National Academy of Sciences of the United States of America, 1986
- Calcitonin gene-related peptide is a potent vasodilatorNature, 1985